- Home
- VABK vs AVTX Comparison
VABK vs AVTX Comparison
Compare VABK & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VABK | AVTX |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | VABK | AVTX |
|---|---|---|
| Price | $40.50 | $15.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.29 |
| AVG Volume (30 Days) | 5.8K | ★ 306.4K |
| Earning Date | 01-23-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 14.22 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $56,512,000.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.01 | ★ N/A |
| Revenue Growth | ★ 10.39 | N/A |
| 52 Week Low | $34.12 | $3.39 |
| 52 Week High | $44.57 | $20.72 |
Technical Indicators
Market Signals| Indicator | VABK | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 41.76 |
| Support Level | $39.10 | $14.50 |
| Resistance Level | $40.43 | $17.12 |
| Average True Range (ATR) | 0.63 | 1.03 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 65.12 | 25.25 |
Price Performance
Historical ComparisonAbout VABK Virginia National Bankshares Corporation
Virginia National Bankshares Corp is a bank holding company which is engaged in the commercial and retail banking business. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts and other depository services. Its segments include the Bank, VNB Trust and Estate Services, Sturman Wealth Advisors, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits and offering related services to individuals, businesses, and charitable organizations.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).